Merck and Co., Inc.

14 Archived Projects

Title Investigator Start End
HIV Treatment Training for Clinical Setting Hare
A Probe to Evaluate the Safety, Tolerability & Immunogenicity of the MRK Adenovirus Serotype 5 Vector Human Immunodeficiency Virus Type 1 gag Vaccine in HIV-1 Infected Luetkemeyer
Merck Drug Donation for Antiretroviral Therapy of AIDS-Related Kaposi Sarcoma in Africa Martin
Raltegravir (MK-518) Aweeka
Raltegravir Intensification in Antiretroviral-Treated Patients Exhibiting a Suboptimal CD4+T Cell Response Deeks
The Impact of Anogenital Human Papillomavirus in the Transmission of HIV in Urban Brazil: Phase II Study Palefsky
Treating HIV-Infected Elite Controllers as a Model of HIV Remission Hatano
Phase I Parallel Protocol of MK-8669 (Ridaforolimus) + MK-2206 and MK-8669 (Ridaforolimus) + MK-0752 Doublets (MKMK) in Patients with Advanced Cancer
A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, in 16- to 26- Year-Old Men and 16- to 26- Year-Old Women Palefsky
DAIDS A5298 Study: A Randomized, Double-Blinded, Placebo-Controlled, Phase III Trial of the Quadrivalent HPV Vaccine to Prevent Anal Human Papillomavirus Infection in HIV-Infected Men Luetkemeyer
ACE-Inhibitors to Decrease Lymphoid Fibrosis and the Size of the Latent Reservoir in Antiretroviral-Treated, HIV-infected Patients: A Randomized, Placebo-Controlled Study Hatano
ACTG A5294: A Prospective, Phase III Open-Label Study of Response-Guided Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in HCV/HIV Coinfected Subjects Luetkemeyer
Merck Men's Efficacy Study, V501 Palefsky
GINI: Gardasil Immunogenicity with Needle-free Injection-Safety and Immunogenicity of Gardasil using IM and ID needle-free injection delivery Palefsky